$Bionano Genomics Inc Their genome analysis platform has already been described as potentially, or even likely, best-in-class by several independent reviews and experts. However, the company apparently isn't good at marketing bc adoption has really underperformed expectations. It's kind of risky buying off of this PR since ER is tmrw. It's AH tmrw, so at least that gives some time for a bit of a run if volume continues. But the PR itself isn't anything that's too exciting: they've released maybe dozens of these announcements already to no avail.